Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Germany's Healthcare Reforms Herald More Pain for Big Pharma
Donald Trump's push to bring down drug prices in the US has rattled the world's leading pharmaceutical companies. Now, they're confronting a new menace as Germany seeks to plug a ballooning deficit in its public health-insurance funds. Europe's…
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDT Chad Fugure - Vice President of Investor Relations Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP & Member of…
OneSource Specialty Pharma: A capacity-led bet on the GLP-1 gold rush
Demand is no longer the question. The only real variable is the timing of regulatory approvals. And on April 21, 2026, that variable moved sharply in the company's favour. Understanding what OneSource builds OneSource Specialty Pharma was demerged…
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a 'buy' rating to a 'strong-buy' rating in a note issued to investors on Saturday. How Royalty Pharma Prints Cash Without Biotech's Biggest…
Wall Street Zen Upgrades Nuvectis Pharma (NASDAQ:NVCT) to 'Hold'
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a 'sell' rating to a 'hold' rating in a note issued to investors on Saturday. Separately, Weiss Ratings restated a 'sell (e+)' rating on…
Wall Street Zen Downgrades aTyr Pharma (NASDAQ:ATYR) to Sell
aTyr Pharma (NASDAQ:ATYR - Get Free Report) was downgraded by research analysts at Wall Street Zen from a 'hold' rating to a 'sell' rating in a research note issued to investors on Saturday. Separately, Jefferies Financial Group reaffirmed a 'buy'…
NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded by Wall Street Zen to 'Hold' Rating
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a 'sell' rating to a 'hold' rating in a research report issued to clients and investors on Saturday. A number of other research…
Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Earnings Results
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.96), Zacks reports. Zealand Pharma…
UBS Group AG Raises Stock Position in NewAmsterdam Pharma Company N.V. $NAMS
UBS Group AG increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 17.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 899,442 shares of…
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by Wall Street Zen to 'Buy' Rating
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a 'hold' rating to a 'buy' rating in a research note issued on Saturday. Can BioMarin Stock Live Up to Wall Street's High Expectations?
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS
Royalty Pharma (NASDAQ:RPRX - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08, Zacks reports. The…
A Member of Sackler Family Says She Got Addicted to Opioids
Can't-miss innovations from the bleeding edge of science and tech The opioid crisis seems to be coming full circle. As the Sackler family negotiated to pay a $6.5 billion settlement over their role in Purdue Pharma's production of addictive…
Want to ride market volatility? Edelweiss Aggressive Hybrid Fund is a smart choice
Edelweiss Aggressive Hybrid Fund has established itself as one of the consistent performers in the aggressive hybrid fund category. Since becoming eligible for bl.portfolio's Star Track ratings, the scheme has maintained either a four-star or…
Teradata Stock Beats Q1 Estimates, A Cash Flow Generator Riding The AI Wave (NYSE:TDC)
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
GP du Morbihan: Benoît Cosnefroy scores fourth victory at French one-dayer
Benoît Cosnefroy (UAE Team Emirates-XRG) sped to his fourth career victory at the GP du Morbihan and his third in a row, beating the Decathlon-CMA CGM duo of Noa Isidore and Paul Lapeira to the finish line in Plumelec. The Frenchman's 22nd…
Receive a Daily briefing on Pharma Industry News
Get Started